nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—PLA2G4A—Fluocinolone Acetonide—psoriasis	0.586	0.846	CbGbCtD
Orlistat—CYP3A4—Calcitriol—psoriasis	0.0205	0.0295	CbGbCtD
Orlistat—CYP3A4—Methoxsalen—psoriasis	0.0159	0.023	CbGbCtD
Orlistat—CYP3A4—Cholecalciferol—psoriasis	0.0106	0.0152	CbGbCtD
Orlistat—CYP3A4—Mycophenolate mofetil—psoriasis	0.00915	0.0132	CbGbCtD
Orlistat—CYP3A4—Triamcinolone—psoriasis	0.00915	0.0132	CbGbCtD
Orlistat—CYP3A4—Betamethasone—psoriasis	0.00785	0.0113	CbGbCtD
Orlistat—CYP3A4—Prednisolone—psoriasis	0.00775	0.0112	CbGbCtD
Orlistat—CYP3A4—Hydrocortisone—psoriasis	0.00734	0.0106	CbGbCtD
Orlistat—CYP3A4—Prednisone—psoriasis	0.00732	0.0105	CbGbCtD
Orlistat—CYP3A4—Cyclosporine—psoriasis	0.00693	0.01	CbGbCtD
Orlistat—CYP3A4—Dexamethasone—psoriasis	0.00457	0.00659	CbGbCtD
Orlistat—PLA2G7—Synthesis, secretion, and deacylation of Ghrelin—LEP—psoriasis	0.00384	0.0754	CbGpPWpGaD
Orlistat—FASN—Mycophenolate mofetil—Mycophenolic acid—psoriasis	0.00342	0.494	CbGdCrCtD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—ICAM1—psoriasis	0.00274	0.0538	CbGpPWpGaD
Orlistat—PLA2G7—Peptide hormone metabolism—REN—psoriasis	0.00273	0.0537	CbGpPWpGaD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—IFNG—psoriasis	0.00208	0.0409	CbGpPWpGaD
Orlistat—FASN—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00193	0.279	CbGdCrCtD
Orlistat—FASN—Activation of gene expression by SREBF (SREBP)—CARM1—psoriasis	0.0018	0.0354	CbGpPWpGaD
Orlistat—PLA2G7—IL1 and megakaryotyces in obesity—NFKB1—psoriasis	0.00173	0.034	CbGpPWpGaD
Orlistat—PLA2G7—Peptide hormone metabolism—ACE—psoriasis	0.00171	0.0335	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—SERPINB8—psoriasis	0.00151	0.0296	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—SERPINB8—psoriasis	0.00151	0.0296	CbGpPWpGaD
Orlistat—FASN—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CARM1—psoriasis	0.00144	0.0282	CbGpPWpGaD
Orlistat—PNLIP—Retinoid metabolism and transport—APOE—psoriasis	0.00119	0.0234	CbGpPWpGaD
Orlistat—PLA2G7—Peptide hormone metabolism—LEP—psoriasis	0.00106	0.0208	CbGpPWpGaD
Orlistat—PNLIP—Lipid and lipoprotein metabolism—APOE—psoriasis	0.00102	0.02	CbGpPWpGaD
Orlistat—FASN—Validated transcriptional targets of deltaNp63 isoforms—VDR—psoriasis	0.000945	0.0186	CbGpPWpGaD
Orlistat—DAGLA—tendon—psoriasis	0.000721	0.266	CbGeAlD
Orlistat—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000645	0.0127	CbGpPWpGaD
Orlistat—PNLIP—Diseases associated with visual transduction—APOE—psoriasis	0.000609	0.012	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—HCAR2—psoriasis	0.000577	0.0113	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—HCAR2—psoriasis	0.000577	0.0113	CbGpPWpGaD
Orlistat—DAGLB—tendon—psoriasis	0.000559	0.206	CbGeAlD
Orlistat—FASN—AMPK Signaling—LEP—psoriasis	0.000556	0.0109	CbGpPWpGaD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.00054	0.0106	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—HCAR2—psoriasis	0.000524	0.0103	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—HCAR2—psoriasis	0.000524	0.0103	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—REN—psoriasis	0.000516	0.0101	CbGpPWpGaD
Orlistat—FASN—SREBP signalling—PPARG—psoriasis	0.000484	0.00952	CbGpPWpGaD
Orlistat—PLA2G4A—Raltitrexed—Methotrexate—psoriasis	0.000458	0.0662	CbGdCrCtD
Orlistat—PLA2G7—tendon—psoriasis	0.000452	0.166	CbGeAlD
Orlistat—DAGLB—Hemostasis—ITGAL—psoriasis	0.000438	0.0086	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—ITGAL—psoriasis	0.000438	0.0086	CbGpPWpGaD
Orlistat—ABHD16A—tendon—psoriasis	0.000424	0.156	CbGeAlD
Orlistat—ABHD12—tendon—psoriasis	0.000397	0.146	CbGeAlD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000383	0.00752	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—SERPINB8—psoriasis	0.000379	0.00745	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—NFKBIA—psoriasis	0.000351	0.0069	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—NDUFA5—psoriasis	0.000326	0.00641	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—ACE—psoriasis	0.000322	0.00633	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—HCAR2—psoriasis	0.000309	0.00608	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—HCAR2—psoriasis	0.000309	0.00608	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000304	0.00598	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CCL20—psoriasis	0.0003	0.00589	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—CCL20—psoriasis	0.0003	0.00589	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000292	0.00573	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000292	0.00573	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000288	0.00565	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CYP2S1—psoriasis	0.000277	0.00545	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—CCL20—psoriasis	0.000272	0.00535	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CCL20—psoriasis	0.000272	0.00535	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TAGAP—psoriasis	0.000268	0.00527	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TAGAP—psoriasis	0.000268	0.00527	CbGpPWpGaD
Orlistat—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000268	0.00526	CbGpPWpGaD
Orlistat—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000264	0.00519	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—HCAR2—psoriasis	0.000256	0.00504	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000254	0.00499	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—JUN—psoriasis	0.000233	0.00457	CbGpPWpGaD
Orlistat—FASN—Metabolism—NDUFA5—psoriasis	0.000231	0.00453	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—NOS2—psoriasis	0.00023	0.00453	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—NFKBIA—psoriasis	0.00023	0.00453	CbGpPWpGaD
Orlistat—FASN—AMPK Signaling—TP53—psoriasis	0.000227	0.00446	CbGpPWpGaD
Orlistat—FASN—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000225	0.00442	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TAGAP—psoriasis	0.000222	0.00437	CbGpPWpGaD
Orlistat—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000217	0.00427	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000215	0.00423	CbGpPWpGaD
Orlistat—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000214	0.00421	CbGpPWpGaD
Orlistat—DAGLA—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.000202	0.00396	CbGpPWpGaD
Orlistat—DAGLB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	0.000202	0.00396	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet homeostasis—NOS2—psoriasis	0.000202	0.00396	CbGpPWpGaD
Orlistat—PLA2G4A—PDGF Pathway—STAT3—psoriasis	0.000201	0.00396	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—LEP—psoriasis	0.0002	0.00393	CbGpPWpGaD
Orlistat—FASN—Metabolism—CYP2S1—psoriasis	0.000196	0.00386	CbGpPWpGaD
Orlistat—DAGLA—Hemostasis—NOS2—psoriasis	0.00018	0.00353	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—NOS2—psoriasis	0.00018	0.00353	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000167	0.00329	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—psoriasis	0.000163	0.0032	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CCL20—psoriasis	0.000161	0.00316	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CCL20—psoriasis	0.000161	0.00316	CbGpPWpGaD
Orlistat—PLA2G4A—tendon—psoriasis	0.00016	0.0591	CbGeAlD
Orlistat—PLA2G4A—Endothelins—JUN—psoriasis	0.000159	0.00312	CbGpPWpGaD
Orlistat—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—NFKB1—psoriasis	0.000157	0.00308	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—JUN—psoriasis	0.000153	0.003	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—NFKB1—psoriasis	0.000147	0.00289	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000145	0.00286	CbGpPWpGaD
Orlistat—DAGLB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.000143	0.0028	CbGpPWpGaD
Orlistat—DAGLA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.000143	0.0028	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—CARM1—psoriasis	0.000135	0.00266	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CCL20—psoriasis	0.000133	0.00262	CbGpPWpGaD
Orlistat—PLA2G7—Metabolism of proteins—CXCL8—psoriasis	0.000133	0.00261	CbGpPWpGaD
Orlistat—PLA2G4A—AGE/RAGE pathway—STAT3—psoriasis	0.000132	0.0026	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—HCAR2—psoriasis	0.000132	0.00259	CbGpPWpGaD
Orlistat—PNLIP—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000127	0.00249	CbGpPWpGaD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000123	0.00242	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000117	0.0023	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000115	0.00227	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000114	0.00223	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—ITGAL—psoriasis	0.00011	0.00216	CbGpPWpGaD
Orlistat—PLA2G4A—Dexamethasone—Clobetasol propionate—psoriasis	0.000108	0.0156	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Clobetasol propionate—psoriasis	0.000108	0.0156	CbGdCrCtD
Orlistat—Malaise—Betamethasone—psoriasis	0.000105	0.000428	CcSEcCtD
Orlistat—Anaphylactic shock—Triamcinolone—psoriasis	0.000105	0.000427	CcSEcCtD
Orlistat—Oedema—Triamcinolone—psoriasis	0.000105	0.000427	CcSEcCtD
Orlistat—Vertigo—Betamethasone—psoriasis	0.000105	0.000426	CcSEcCtD
Orlistat—Vertigo—Dexamethasone—psoriasis	0.000105	0.000426	CcSEcCtD
Orlistat—Pain—Mycophenolate mofetil—psoriasis	0.000105	0.000425	CcSEcCtD
Orlistat—Infection—Triamcinolone—psoriasis	0.000104	0.000424	CcSEcCtD
Orlistat—DAGLA—Hemostasis—VEGFA—psoriasis	0.000104	0.00204	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—VEGFA—psoriasis	0.000104	0.00204	CbGpPWpGaD
Orlistat—Feeling abnormal—Cyclosporine—psoriasis	0.000103	0.00042	CcSEcCtD
Orlistat—Insomnia—Prednisolone—psoriasis	0.000103	0.00042	CcSEcCtD
Orlistat—Alopecia—Prednisone—psoriasis	0.000103	0.000419	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000103	0.00202	CbGpPWpGaD
Orlistat—Hepatobiliary disease—Methotrexate—psoriasis	0.000103	0.000418	CcSEcCtD
Orlistat—Gastrointestinal pain—Cyclosporine—psoriasis	0.000103	0.000417	CcSEcCtD
Orlistat—Dizziness—Mycophenolic acid—psoriasis	0.000103	0.000417	CcSEcCtD
Orlistat—Paraesthesia—Prednisolone—psoriasis	0.000103	0.000417	CcSEcCtD
Orlistat—Mental disorder—Prednisone—psoriasis	0.000102	0.000416	CcSEcCtD
Orlistat—Malnutrition—Prednisone—psoriasis	0.000102	0.000413	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000102	0.000413	CcSEcCtD
Orlistat—Hyperhidrosis—Triamcinolone—psoriasis	0.000101	0.000412	CcSEcCtD
Orlistat—Convulsion—Dexamethasone—psoriasis	0.000101	0.000411	CcSEcCtD
Orlistat—Convulsion—Betamethasone—psoriasis	0.000101	0.000411	CcSEcCtD
Orlistat—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000101	0.00041	CcSEcCtD
Orlistat—Insomnia—Hydrocortisone—psoriasis	0.000101	0.00041	CcSEcCtD
Orlistat—Paraesthesia—Hydrocortisone—psoriasis	0.0001	0.000407	CcSEcCtD
Orlistat—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.0001	0.000407	CcSEcCtD
Orlistat—Urticaria—Cyclosporine—psoriasis	9.97e-05	0.000405	CcSEcCtD
Orlistat—CYP3A4—Tryptophan metabolism—CAT—psoriasis	9.95e-05	0.00196	CbGpPWpGaD
Orlistat—Myalgia—Betamethasone—psoriasis	9.94e-05	0.000404	CcSEcCtD
Orlistat—Myalgia—Dexamethasone—psoriasis	9.94e-05	0.000404	CcSEcCtD
Orlistat—Abdominal pain—Cyclosporine—psoriasis	9.92e-05	0.000403	CcSEcCtD
Orlistat—Body temperature increased—Cyclosporine—psoriasis	9.92e-05	0.000403	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—NDUFA5—psoriasis	9.9e-05	0.00195	CbGpPWpGaD
Orlistat—Anxiety—Betamethasone—psoriasis	9.9e-05	0.000402	CcSEcCtD
Orlistat—Anxiety—Dexamethasone—psoriasis	9.9e-05	0.000402	CcSEcCtD
Orlistat—Vomiting—Mycophenolic acid—psoriasis	9.86e-05	0.000401	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	9.85e-05	0.00194	CbGpPWpGaD
Orlistat—Discomfort—Betamethasone—psoriasis	9.82e-05	0.000399	CcSEcCtD
Orlistat—Discomfort—Dexamethasone—psoriasis	9.82e-05	0.000399	CcSEcCtD
Orlistat—Dyspepsia—Hydrocortisone—psoriasis	9.81e-05	0.000399	CcSEcCtD
Orlistat—Haemoglobin—Methotrexate—psoriasis	9.81e-05	0.000399	CcSEcCtD
Orlistat—Rash—Mycophenolic acid—psoriasis	9.78e-05	0.000397	CcSEcCtD
Orlistat—Dermatitis—Mycophenolic acid—psoriasis	9.77e-05	0.000397	CcSEcCtD
Orlistat—Pain—Prednisolone—psoriasis	9.76e-05	0.000397	CcSEcCtD
Orlistat—Haemorrhage—Methotrexate—psoriasis	9.76e-05	0.000397	CcSEcCtD
Orlistat—Hepatitis—Methotrexate—psoriasis	9.76e-05	0.000397	CcSEcCtD
Orlistat—Urticaria—Mycophenolate mofetil—psoriasis	9.72e-05	0.000395	CcSEcCtD
Orlistat—Headache—Mycophenolic acid—psoriasis	9.71e-05	0.000395	CcSEcCtD
Orlistat—Decreased appetite—Hydrocortisone—psoriasis	9.69e-05	0.000394	CcSEcCtD
Orlistat—Pharyngitis—Methotrexate—psoriasis	9.68e-05	0.000394	CcSEcCtD
Orlistat—Body temperature increased—Mycophenolate mofetil—psoriasis	9.67e-05	0.000393	CcSEcCtD
Orlistat—Abdominal pain—Mycophenolate mofetil—psoriasis	9.67e-05	0.000393	CcSEcCtD
Orlistat—Urinary tract disorder—Methotrexate—psoriasis	9.64e-05	0.000392	CcSEcCtD
Orlistat—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.63e-05	0.000391	CcSEcCtD
Orlistat—Fatigue—Hydrocortisone—psoriasis	9.61e-05	0.000391	CcSEcCtD
Orlistat—FASN—Metabolism—CARM1—psoriasis	9.58e-05	0.00188	CbGpPWpGaD
Orlistat—Vision blurred—Prednisone—psoriasis	9.58e-05	0.000389	CcSEcCtD
Orlistat—Urethral disorder—Methotrexate—psoriasis	9.57e-05	0.000389	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.56e-05	0.000389	CcSEcCtD
Orlistat—Pain—Hydrocortisone—psoriasis	9.53e-05	0.000387	CcSEcCtD
Orlistat—Oedema—Betamethasone—psoriasis	9.53e-05	0.000387	CcSEcCtD
Orlistat—Anaphylactic shock—Betamethasone—psoriasis	9.53e-05	0.000387	CcSEcCtD
Orlistat—Oedema—Dexamethasone—psoriasis	9.53e-05	0.000387	CcSEcCtD
Orlistat—Anaphylactic shock—Dexamethasone—psoriasis	9.53e-05	0.000387	CcSEcCtD
Orlistat—Insomnia—Triamcinolone—psoriasis	9.49e-05	0.000386	CcSEcCtD
Orlistat—Infection—Betamethasone—psoriasis	9.46e-05	0.000385	CcSEcCtD
Orlistat—Infection—Dexamethasone—psoriasis	9.46e-05	0.000385	CcSEcCtD
Orlistat—Ill-defined disorder—Prednisone—psoriasis	9.43e-05	0.000383	CcSEcCtD
Orlistat—Paraesthesia—Triamcinolone—psoriasis	9.43e-05	0.000383	CcSEcCtD
Orlistat—Feeling abnormal—Prednisolone—psoriasis	9.41e-05	0.000382	CcSEcCtD
Orlistat—Nervous system disorder—Betamethasone—psoriasis	9.34e-05	0.00038	CcSEcCtD
Orlistat—Nervous system disorder—Dexamethasone—psoriasis	9.34e-05	0.00038	CcSEcCtD
Orlistat—Angioedema—Prednisone—psoriasis	9.29e-05	0.000377	CcSEcCtD
Orlistat—Hypersensitivity—Cyclosporine—psoriasis	9.24e-05	0.000376	CcSEcCtD
Orlistat—Dyspepsia—Triamcinolone—psoriasis	9.24e-05	0.000376	CcSEcCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.23e-05	0.00181	CbGpPWpGaD
Orlistat—Nausea—Mycophenolic acid—psoriasis	9.21e-05	0.000374	CcSEcCtD
Orlistat—Hyperhidrosis—Betamethasone—psoriasis	9.21e-05	0.000374	CcSEcCtD
Orlistat—Hyperhidrosis—Dexamethasone—psoriasis	9.21e-05	0.000374	CcSEcCtD
Orlistat—Feeling abnormal—Hydrocortisone—psoriasis	9.19e-05	0.000373	CcSEcCtD
Orlistat—Malaise—Prednisone—psoriasis	9.17e-05	0.000373	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—JUN—psoriasis	9.16e-05	0.0018	CbGpPWpGaD
Orlistat—Vertigo—Prednisone—psoriasis	9.13e-05	0.000371	CcSEcCtD
Orlistat—Gastrointestinal pain—Hydrocortisone—psoriasis	9.12e-05	0.000371	CcSEcCtD
Orlistat—Urticaria—Prednisolone—psoriasis	9.07e-05	0.000369	CcSEcCtD
Orlistat—Fatigue—Triamcinolone—psoriasis	9.05e-05	0.000368	CcSEcCtD
Orlistat—Hypersensitivity—Mycophenolate mofetil—psoriasis	9.02e-05	0.000366	CcSEcCtD
Orlistat—Asthenia—Cyclosporine—psoriasis	9e-05	0.000366	CcSEcCtD
Orlistat—Pain—Triamcinolone—psoriasis	8.98e-05	0.000365	CcSEcCtD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.96e-05	0.00176	CbGpPWpGaD
Orlistat—Pruritus—Cyclosporine—psoriasis	8.88e-05	0.000361	CcSEcCtD
Orlistat—Urticaria—Hydrocortisone—psoriasis	8.86e-05	0.00036	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—SOCS1—psoriasis	8.85e-05	0.00174	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—SOCS1—psoriasis	8.85e-05	0.00174	CbGpPWpGaD
Orlistat—Immune system disorder—Methotrexate—psoriasis	8.81e-05	0.000358	CcSEcCtD
Orlistat—Abdominal pain—Hydrocortisone—psoriasis	8.81e-05	0.000358	CcSEcCtD
Orlistat—Body temperature increased—Hydrocortisone—psoriasis	8.81e-05	0.000358	CcSEcCtD
Orlistat—Convulsion—Prednisone—psoriasis	8.81e-05	0.000358	CcSEcCtD
Orlistat—Mediastinal disorder—Methotrexate—psoriasis	8.79e-05	0.000357	CcSEcCtD
Orlistat—Asthenia—Mycophenolate mofetil—psoriasis	8.78e-05	0.000357	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Betamethasone—psoriasis	8.68e-05	0.000353	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.68e-05	0.000353	CcSEcCtD
Orlistat—Pruritus—Mycophenolate mofetil—psoriasis	8.66e-05	0.000352	CcSEcCtD
Orlistat—Myalgia—Prednisone—psoriasis	8.65e-05	0.000352	CcSEcCtD
Orlistat—Feeling abnormal—Triamcinolone—psoriasis	8.65e-05	0.000352	CcSEcCtD
Orlistat—PLA2G4A—Betamethasone—Fluocinonide—psoriasis	8.64e-05	0.0125	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Beclomethasone—psoriasis	8.64e-05	0.0125	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Fluocinonide—psoriasis	8.64e-05	0.0125	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Beclomethasone—psoriasis	8.64e-05	0.0125	CbGdCrCtD
Orlistat—Anxiety—Prednisone—psoriasis	8.62e-05	0.00035	CcSEcCtD
Orlistat—Alopecia—Methotrexate—psoriasis	8.62e-05	0.00035	CcSEcCtD
Orlistat—Insomnia—Betamethasone—psoriasis	8.62e-05	0.00035	CcSEcCtD
Orlistat—Insomnia—Dexamethasone—psoriasis	8.62e-05	0.00035	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	8.59e-05	0.000349	CcSEcCtD
Orlistat—Diarrhoea—Cyclosporine—psoriasis	8.58e-05	0.000349	CcSEcCtD
Orlistat—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.57e-05	0.00169	CbGpPWpGaD
Orlistat—Paraesthesia—Betamethasone—psoriasis	8.55e-05	0.000348	CcSEcCtD
Orlistat—Paraesthesia—Dexamethasone—psoriasis	8.55e-05	0.000348	CcSEcCtD
Orlistat—Discomfort—Prednisone—psoriasis	8.55e-05	0.000347	CcSEcCtD
Orlistat—Mental disorder—Methotrexate—psoriasis	8.55e-05	0.000347	CcSEcCtD
Orlistat—Malnutrition—Methotrexate—psoriasis	8.49e-05	0.000345	CcSEcCtD
Orlistat—DAGLB—Signaling by GPCR—TYK2—psoriasis	8.44e-05	0.00166	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—TYK2—psoriasis	8.44e-05	0.00166	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2S1—psoriasis	8.42e-05	0.00165	CbGpPWpGaD
Orlistat—Hypersensitivity—Prednisolone—psoriasis	8.41e-05	0.000342	CcSEcCtD
Orlistat—PLA2G4A—Betamethasone—Fluocinolone Acetonide—psoriasis	8.4e-05	0.0121	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Fluocinolone Acetonide—psoriasis	8.4e-05	0.0121	CbGdCrCtD
Orlistat—Dyspepsia—Dexamethasone—psoriasis	8.38e-05	0.000341	CcSEcCtD
Orlistat—Dyspepsia—Betamethasone—psoriasis	8.38e-05	0.000341	CcSEcCtD
Orlistat—Diarrhoea—Mycophenolate mofetil—psoriasis	8.37e-05	0.00034	CcSEcCtD
Orlistat—Urticaria—Triamcinolone—psoriasis	8.34e-05	0.000339	CcSEcCtD
Orlistat—PNLIP—Metabolism—CAT—psoriasis	8.33e-05	0.00164	CbGpPWpGaD
Orlistat—Dysgeusia—Methotrexate—psoriasis	8.32e-05	0.000338	CcSEcCtD
Orlistat—Body temperature increased—Triamcinolone—psoriasis	8.3e-05	0.000337	CcSEcCtD
Orlistat—Dizziness—Cyclosporine—psoriasis	8.3e-05	0.000337	CcSEcCtD
Orlistat—Oedema—Prednisone—psoriasis	8.3e-05	0.000337	CcSEcCtD
Orlistat—Anaphylactic shock—Prednisone—psoriasis	8.3e-05	0.000337	CcSEcCtD
Orlistat—Decreased appetite—Betamethasone—psoriasis	8.28e-05	0.000337	CcSEcCtD
Orlistat—Decreased appetite—Dexamethasone—psoriasis	8.28e-05	0.000337	CcSEcCtD
Orlistat—PNLIP—Disease—HLA-A—psoriasis	8.28e-05	0.00163	CbGpPWpGaD
Orlistat—Infection—Prednisone—psoriasis	8.24e-05	0.000335	CcSEcCtD
Orlistat—Gastrointestinal disorder—Dexamethasone—psoriasis	8.22e-05	0.000334	CcSEcCtD
Orlistat—Gastrointestinal disorder—Betamethasone—psoriasis	8.22e-05	0.000334	CcSEcCtD
Orlistat—Back pain—Methotrexate—psoriasis	8.22e-05	0.000334	CcSEcCtD
Orlistat—Hypersensitivity—Hydrocortisone—psoriasis	8.21e-05	0.000334	CcSEcCtD
Orlistat—Fatigue—Betamethasone—psoriasis	8.21e-05	0.000334	CcSEcCtD
Orlistat—Fatigue—Dexamethasone—psoriasis	8.21e-05	0.000334	CcSEcCtD
Orlistat—Pain—Dexamethasone—psoriasis	8.15e-05	0.000331	CcSEcCtD
Orlistat—Pain—Betamethasone—psoriasis	8.15e-05	0.000331	CcSEcCtD
Orlistat—Nervous system disorder—Prednisone—psoriasis	8.14e-05	0.000331	CcSEcCtD
Orlistat—Dizziness—Mycophenolate mofetil—psoriasis	8.09e-05	0.000329	CcSEcCtD
Orlistat—DAGLB—GPCR downstream signaling—CXCL8—psoriasis	8.09e-05	0.00159	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—CXCL8—psoriasis	8.09e-05	0.00159	CbGpPWpGaD
Orlistat—Skin disorder—Prednisone—psoriasis	8.06e-05	0.000327	CcSEcCtD
Orlistat—Hyperhidrosis—Prednisone—psoriasis	8.02e-05	0.000326	CcSEcCtD
Orlistat—Vision blurred—Methotrexate—psoriasis	8.01e-05	0.000325	CcSEcCtD
Orlistat—Asthenia—Hydrocortisone—psoriasis	8e-05	0.000325	CcSEcCtD
Orlistat—Vomiting—Cyclosporine—psoriasis	7.98e-05	0.000324	CcSEcCtD
Orlistat—PLA2G4A—PDGFR-beta signaling pathway—STAT3—psoriasis	7.93e-05	0.00156	CbGpPWpGaD
Orlistat—Rash—Cyclosporine—psoriasis	7.91e-05	0.000321	CcSEcCtD
Orlistat—Dermatitis—Cyclosporine—psoriasis	7.9e-05	0.000321	CcSEcCtD
Orlistat—Pruritus—Hydrocortisone—psoriasis	7.89e-05	0.000321	CcSEcCtD
Orlistat—Ill-defined disorder—Methotrexate—psoriasis	7.88e-05	0.00032	CcSEcCtD
Orlistat—Headache—Cyclosporine—psoriasis	7.86e-05	0.000319	CcSEcCtD
Orlistat—DAGLA—Hemostasis—TP53—psoriasis	7.86e-05	0.00154	CbGpPWpGaD
Orlistat—DAGLB—Hemostasis—TP53—psoriasis	7.86e-05	0.00154	CbGpPWpGaD
Orlistat—Feeling abnormal—Dexamethasone—psoriasis	7.85e-05	0.000319	CcSEcCtD
Orlistat—Feeling abnormal—Betamethasone—psoriasis	7.85e-05	0.000319	CcSEcCtD
Orlistat—Gastrointestinal pain—Betamethasone—psoriasis	7.79e-05	0.000317	CcSEcCtD
Orlistat—Gastrointestinal pain—Dexamethasone—psoriasis	7.79e-05	0.000317	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—HCAR2—psoriasis	7.79e-05	0.00153	CbGpPWpGaD
Orlistat—Vomiting—Mycophenolate mofetil—psoriasis	7.78e-05	0.000316	CcSEcCtD
Orlistat—Hypersensitivity—Triamcinolone—psoriasis	7.73e-05	0.000314	CcSEcCtD
Orlistat—PNLIP—Disease—APOE—psoriasis	7.73e-05	0.00152	CbGpPWpGaD
Orlistat—Rash—Mycophenolate mofetil—psoriasis	7.72e-05	0.000314	CcSEcCtD
Orlistat—Dermatitis—Mycophenolate mofetil—psoriasis	7.71e-05	0.000313	CcSEcCtD
Orlistat—Headache—Mycophenolate mofetil—psoriasis	7.67e-05	0.000312	CcSEcCtD
Orlistat—Malaise—Methotrexate—psoriasis	7.66e-05	0.000311	CcSEcCtD
Orlistat—Vertigo—Methotrexate—psoriasis	7.63e-05	0.00031	CcSEcCtD
Orlistat—Diarrhoea—Hydrocortisone—psoriasis	7.63e-05	0.00031	CcSEcCtD
Orlistat—Urticaria—Betamethasone—psoriasis	7.57e-05	0.000308	CcSEcCtD
Orlistat—Urticaria—Dexamethasone—psoriasis	7.57e-05	0.000308	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Prednisone—psoriasis	7.56e-05	0.000307	CcSEcCtD
Orlistat—Dizziness—Prednisolone—psoriasis	7.55e-05	0.000307	CcSEcCtD
Orlistat—Asthenia—Triamcinolone—psoriasis	7.53e-05	0.000306	CcSEcCtD
Orlistat—Abdominal pain—Dexamethasone—psoriasis	7.53e-05	0.000306	CcSEcCtD
Orlistat—Abdominal pain—Betamethasone—psoriasis	7.53e-05	0.000306	CcSEcCtD
Orlistat—Body temperature increased—Betamethasone—psoriasis	7.53e-05	0.000306	CcSEcCtD
Orlistat—Body temperature increased—Dexamethasone—psoriasis	7.53e-05	0.000306	CcSEcCtD
Orlistat—Insomnia—Prednisone—psoriasis	7.5e-05	0.000305	CcSEcCtD
Orlistat—Nausea—Cyclosporine—psoriasis	7.45e-05	0.000303	CcSEcCtD
Orlistat—Paraesthesia—Prednisone—psoriasis	7.45e-05	0.000303	CcSEcCtD
Orlistat—Pruritus—Triamcinolone—psoriasis	7.43e-05	0.000302	CcSEcCtD
Orlistat—Cough—Methotrexate—psoriasis	7.41e-05	0.000301	CcSEcCtD
Orlistat—Dizziness—Hydrocortisone—psoriasis	7.37e-05	0.0003	CcSEcCtD
Orlistat—Convulsion—Methotrexate—psoriasis	7.36e-05	0.000299	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—CXCL8—psoriasis	7.35e-05	0.00144	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—CXCL8—psoriasis	7.35e-05	0.00144	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—SOCS1—psoriasis	7.33e-05	0.00144	CbGpPWpGaD
Orlistat—Dyspepsia—Prednisone—psoriasis	7.3e-05	0.000297	CcSEcCtD
Orlistat—Nausea—Mycophenolate mofetil—psoriasis	7.27e-05	0.000295	CcSEcCtD
Orlistat—Myalgia—Methotrexate—psoriasis	7.23e-05	0.000294	CcSEcCtD
Orlistat—Chest pain—Methotrexate—psoriasis	7.23e-05	0.000294	CcSEcCtD
Orlistat—Decreased appetite—Prednisone—psoriasis	7.21e-05	0.000293	CcSEcCtD
Orlistat—PNLIP—Disease—NOS2—psoriasis	7.2e-05	0.00142	CbGpPWpGaD
Orlistat—Rash—Prednisolone—psoriasis	7.2e-05	0.000293	CcSEcCtD
Orlistat—Dermatitis—Prednisolone—psoriasis	7.19e-05	0.000292	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	7.18e-05	0.000292	CcSEcCtD
Orlistat—Fatigue—Prednisone—psoriasis	7.15e-05	0.000291	CcSEcCtD
Orlistat—Headache—Prednisolone—psoriasis	7.15e-05	0.000291	CcSEcCtD
Orlistat—Discomfort—Methotrexate—psoriasis	7.15e-05	0.00029	CcSEcCtD
Orlistat—Vomiting—Hydrocortisone—psoriasis	7.09e-05	0.000288	CcSEcCtD
Orlistat—Rash—Hydrocortisone—psoriasis	7.03e-05	0.000286	CcSEcCtD
Orlistat—Dermatitis—Hydrocortisone—psoriasis	7.02e-05	0.000285	CcSEcCtD
Orlistat—Headache—Hydrocortisone—psoriasis	6.98e-05	0.000284	CcSEcCtD
Orlistat—Dizziness—Triamcinolone—psoriasis	6.94e-05	0.000282	CcSEcCtD
Orlistat—Anaphylactic shock—Methotrexate—psoriasis	6.93e-05	0.000282	CcSEcCtD
Orlistat—Infection—Methotrexate—psoriasis	6.89e-05	0.00028	CcSEcCtD
Orlistat—PLA2G4A—Signaling by GPCR—CCL20—psoriasis	6.85e-05	0.00135	CbGpPWpGaD
Orlistat—Feeling abnormal—Prednisone—psoriasis	6.84e-05	0.000278	CcSEcCtD
Orlistat—Asthenia—Dexamethasone—psoriasis	6.83e-05	0.000278	CcSEcCtD
Orlistat—Asthenia—Betamethasone—psoriasis	6.83e-05	0.000278	CcSEcCtD
Orlistat—Nervous system disorder—Methotrexate—psoriasis	6.8e-05	0.000276	CcSEcCtD
Orlistat—Gastrointestinal pain—Prednisone—psoriasis	6.78e-05	0.000276	CcSEcCtD
Orlistat—Nausea—Prednisolone—psoriasis	6.78e-05	0.000276	CcSEcCtD
Orlistat—PLA2G4A—Signaling Pathways—TAGAP—psoriasis	6.75e-05	0.00133	CbGpPWpGaD
Orlistat—Pruritus—Dexamethasone—psoriasis	6.74e-05	0.000274	CcSEcCtD
Orlistat—Pruritus—Betamethasone—psoriasis	6.74e-05	0.000274	CcSEcCtD
Orlistat—Skin disorder—Methotrexate—psoriasis	6.73e-05	0.000274	CcSEcCtD
Orlistat—Hyperhidrosis—Methotrexate—psoriasis	6.7e-05	0.000272	CcSEcCtD
Orlistat—Vomiting—Triamcinolone—psoriasis	6.67e-05	0.000271	CcSEcCtD
Orlistat—Nausea—Hydrocortisone—psoriasis	6.62e-05	0.000269	CcSEcCtD
Orlistat—Rash—Triamcinolone—psoriasis	6.62e-05	0.000269	CcSEcCtD
Orlistat—Dermatitis—Triamcinolone—psoriasis	6.61e-05	0.000269	CcSEcCtD
Orlistat—Urticaria—Prednisone—psoriasis	6.59e-05	0.000268	CcSEcCtD
Orlistat—Headache—Triamcinolone—psoriasis	6.58e-05	0.000267	CcSEcCtD
Orlistat—Abdominal pain—Prednisone—psoriasis	6.56e-05	0.000267	CcSEcCtD
Orlistat—Body temperature increased—Prednisone—psoriasis	6.56e-05	0.000267	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—APOE—psoriasis	6.53e-05	0.00128	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—LEP—psoriasis	6.53e-05	0.00128	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—APOE—psoriasis	6.53e-05	0.00128	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—LEP—psoriasis	6.53e-05	0.00128	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.53e-05	0.00128	CbGpPWpGaD
Orlistat—Diarrhoea—Betamethasone—psoriasis	6.52e-05	0.000265	CcSEcCtD
Orlistat—Diarrhoea—Dexamethasone—psoriasis	6.52e-05	0.000265	CcSEcCtD
Orlistat—PNLIP—Metabolism—APOE—psoriasis	6.47e-05	0.00127	CbGpPWpGaD
Orlistat—Musculoskeletal discomfort—Methotrexate—psoriasis	6.32e-05	0.000257	CcSEcCtD
Orlistat—Dizziness—Betamethasone—psoriasis	6.3e-05	0.000256	CcSEcCtD
Orlistat—Dizziness—Dexamethasone—psoriasis	6.3e-05	0.000256	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.28e-05	0.00124	CbGpPWpGaD
Orlistat—Insomnia—Methotrexate—psoriasis	6.27e-05	0.000255	CcSEcCtD
Orlistat—Nausea—Triamcinolone—psoriasis	6.24e-05	0.000253	CcSEcCtD
Orlistat—Paraesthesia—Methotrexate—psoriasis	6.23e-05	0.000253	CcSEcCtD
Orlistat—Hypersensitivity—Prednisone—psoriasis	6.11e-05	0.000248	CcSEcCtD
Orlistat—Dyspepsia—Methotrexate—psoriasis	6.1e-05	0.000248	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—NFKBIA—psoriasis	6.09e-05	0.0012	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NFKBIA—psoriasis	6.09e-05	0.0012	CbGpPWpGaD
Orlistat—Vomiting—Betamethasone—psoriasis	6.06e-05	0.000246	CcSEcCtD
Orlistat—Vomiting—Dexamethasone—psoriasis	6.06e-05	0.000246	CcSEcCtD
Orlistat—Decreased appetite—Methotrexate—psoriasis	6.03e-05	0.000245	CcSEcCtD
Orlistat—Rash—Betamethasone—psoriasis	6.01e-05	0.000244	CcSEcCtD
Orlistat—Rash—Dexamethasone—psoriasis	6.01e-05	0.000244	CcSEcCtD
Orlistat—Dermatitis—Dexamethasone—psoriasis	6e-05	0.000244	CcSEcCtD
Orlistat—Dermatitis—Betamethasone—psoriasis	6e-05	0.000244	CcSEcCtD
Orlistat—Gastrointestinal disorder—Methotrexate—psoriasis	5.99e-05	0.000243	CcSEcCtD
Orlistat—Fatigue—Methotrexate—psoriasis	5.98e-05	0.000243	CcSEcCtD
Orlistat—Headache—Dexamethasone—psoriasis	5.97e-05	0.000243	CcSEcCtD
Orlistat—Headache—Betamethasone—psoriasis	5.97e-05	0.000243	CcSEcCtD
Orlistat—Asthenia—Prednisone—psoriasis	5.95e-05	0.000242	CcSEcCtD
Orlistat—Pain—Methotrexate—psoriasis	5.93e-05	0.000241	CcSEcCtD
Orlistat—PNLIP—Disease—TYK2—psoriasis	5.9e-05	0.00116	CbGpPWpGaD
Orlistat—FASN—Metabolism—CAT—psoriasis	5.89e-05	0.00116	CbGpPWpGaD
Orlistat—Pruritus—Prednisone—psoriasis	5.87e-05	0.000239	CcSEcCtD
Orlistat—FASN—Disease—HLA-A—psoriasis	5.86e-05	0.00115	CbGpPWpGaD
Orlistat—Feeling abnormal—Methotrexate—psoriasis	5.71e-05	0.000232	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.7e-05	0.00112	CbGpPWpGaD
Orlistat—Diarrhoea—Prednisone—psoriasis	5.68e-05	0.000231	CcSEcCtD
Orlistat—Gastrointestinal pain—Methotrexate—psoriasis	5.67e-05	0.00023	CcSEcCtD
Orlistat—Nausea—Dexamethasone—psoriasis	5.66e-05	0.00023	CcSEcCtD
Orlistat—Nausea—Betamethasone—psoriasis	5.66e-05	0.00023	CcSEcCtD
Orlistat—PNLIP—Metabolism—PPARG—psoriasis	5.64e-05	0.00111	CbGpPWpGaD
Orlistat—Urticaria—Methotrexate—psoriasis	5.51e-05	0.000224	CcSEcCtD
Orlistat—Dizziness—Prednisone—psoriasis	5.49e-05	0.000223	CcSEcCtD
Orlistat—Abdominal pain—Methotrexate—psoriasis	5.48e-05	0.000223	CcSEcCtD
Orlistat—Body temperature increased—Methotrexate—psoriasis	5.48e-05	0.000223	CcSEcCtD
Orlistat—FASN—Disease—APOE—psoriasis	5.47e-05	0.00107	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—APOE—psoriasis	5.41e-05	0.00106	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—LEP—psoriasis	5.41e-05	0.00106	CbGpPWpGaD
Orlistat—PNLIP—Disease—CD4—psoriasis	5.33e-05	0.00105	CbGpPWpGaD
Orlistat—Vomiting—Prednisone—psoriasis	5.27e-05	0.000214	CcSEcCtD
Orlistat—Rash—Prednisone—psoriasis	5.23e-05	0.000213	CcSEcCtD
Orlistat—Dermatitis—Prednisone—psoriasis	5.23e-05	0.000212	CcSEcCtD
Orlistat—Headache—Prednisone—psoriasis	5.2e-05	0.000211	CcSEcCtD
Orlistat—Hypersensitivity—Methotrexate—psoriasis	5.11e-05	0.000208	CcSEcCtD
Orlistat—FASN—Disease—NOS2—psoriasis	5.1e-05	0.001	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—psoriasis	5.08e-05	0.000997	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NFKBIA—psoriasis	5.04e-05	0.000991	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TYK2—psoriasis	4.99e-05	0.00098	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TYK2—psoriasis	4.99e-05	0.00098	CbGpPWpGaD
Orlistat—Asthenia—Methotrexate—psoriasis	4.97e-05	0.000202	CcSEcCtD
Orlistat—Nausea—Prednisone—psoriasis	4.93e-05	0.0002	CcSEcCtD
Orlistat—Pruritus—Methotrexate—psoriasis	4.9e-05	0.000199	CcSEcCtD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.89e-05	0.000961	CbGpPWpGaD
Orlistat—Diarrhoea—Methotrexate—psoriasis	4.74e-05	0.000193	CcSEcCtD
Orlistat—Dizziness—Methotrexate—psoriasis	4.58e-05	0.000186	CcSEcCtD
Orlistat—FASN—Metabolism—APOE—psoriasis	4.58e-05	0.0009	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—NOS2—psoriasis	4.52e-05	0.000888	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.41e-05	0.000867	CbGpPWpGaD
Orlistat—Vomiting—Methotrexate—psoriasis	4.41e-05	0.000179	CcSEcCtD
Orlistat—Rash—Methotrexate—psoriasis	4.37e-05	0.000178	CcSEcCtD
Orlistat—Dermatitis—Methotrexate—psoriasis	4.37e-05	0.000177	CcSEcCtD
Orlistat—Headache—Methotrexate—psoriasis	4.34e-05	0.000177	CcSEcCtD
Orlistat—DAGLB—Signaling Pathways—CXCL8—psoriasis	4.34e-05	0.000853	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL8—psoriasis	4.34e-05	0.000853	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.31e-05	0.000847	CbGpPWpGaD
Orlistat—PLA2G4A—Betamethasone—Hydrocortisone—psoriasis	4.24e-05	0.00612	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Hydrocortisone—psoriasis	4.24e-05	0.00612	CbGdCrCtD
Orlistat—FASN—Disease—TYK2—psoriasis	4.17e-05	0.00082	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TYK2—psoriasis	4.13e-05	0.000812	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—psoriasis	4.13e-05	0.000812	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—IL6—psoriasis	4.13e-05	0.000811	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—IL6—psoriasis	4.13e-05	0.000811	CbGpPWpGaD
Orlistat—Nausea—Methotrexate—psoriasis	4.12e-05	0.000167	CcSEcCtD
Orlistat—PLA2G4A—Metabolism—CARM1—psoriasis	4.11e-05	0.000808	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCL20—psoriasis	4.04e-05	0.000795	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—JUN—psoriasis	4.04e-05	0.000793	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—JUN—psoriasis	4.04e-05	0.000793	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—psoriasis	3.99e-05	0.000784	CbGpPWpGaD
Orlistat—PLA2G4A—Dexamethasone—Betamethasone—psoriasis	3.94e-05	0.00569	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Dexamethasone—psoriasis	3.94e-05	0.00569	CbGdCrCtD
Orlistat—DAGLB—Signaling Pathways—NFKB1—psoriasis	3.88e-05	0.000763	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—NFKB1—psoriasis	3.88e-05	0.000763	CbGpPWpGaD
Orlistat—PLA2G4A—Dexamethasone—Triamcinolone—psoriasis	3.85e-05	0.00556	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Triamcinolone—psoriasis	3.85e-05	0.00556	CbGdCrCtD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.84e-05	0.000755	CbGpPWpGaD
Orlistat—FASN—Disease—CD4—psoriasis	3.77e-05	0.000742	CbGpPWpGaD
Orlistat—PLA2G4A—Betamethasone—Prednisone—psoriasis	3.65e-05	0.00527	CbGdCrCtD
Orlistat—PLA2G4A—Dexamethasone—Prednisone—psoriasis	3.65e-05	0.00527	CbGdCrCtD
Orlistat—PNLIP—Signaling Pathways—CXCL8—psoriasis	3.6e-05	0.000707	CbGpPWpGaD
Orlistat—PLA2G4A—Dexamethasone—Prednisolone—psoriasis	3.57e-05	0.00515	CbGdCrCtD
Orlistat—PLA2G4A—Betamethasone—Prednisolone—psoriasis	3.57e-05	0.00515	CbGdCrCtD
Orlistat—DAGLA—Signaling Pathways—VEGFA—psoriasis	3.53e-05	0.000693	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—psoriasis	3.53e-05	0.000693	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—psoriasis	3.49e-05	0.000686	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—psoriasis	3.49e-05	0.000686	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—JUN—psoriasis	3.34e-05	0.000657	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—NFKB1—psoriasis	3.22e-05	0.000633	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—psoriasis	2.92e-05	0.000574	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—psoriasis	2.92e-05	0.000574	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—psoriasis	2.89e-05	0.000568	CbGpPWpGaD
Orlistat—PNLIP—Disease—IL6—psoriasis	2.89e-05	0.000567	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—psoriasis	2.66e-05	0.000523	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—psoriasis	2.66e-05	0.000523	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—psoriasis	2.62e-05	0.000514	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAT—psoriasis	2.53e-05	0.000497	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL6—psoriasis	2.44e-05	0.000479	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL6—psoriasis	2.44e-05	0.000479	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NDUFA5—psoriasis	2.32e-05	0.000456	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SOCS1—psoriasis	2.23e-05	0.000438	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—psoriasis	2.21e-05	0.000434	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—TYK2—psoriasis	2.12e-05	0.000417	CbGpPWpGaD
Orlistat—FASN—Disease—IL6—psoriasis	2.04e-05	0.000401	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL6—psoriasis	2.02e-05	0.000397	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—psoriasis	1.98e-05	0.000388	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2S1—psoriasis	1.97e-05	0.000388	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—APOE—psoriasis	1.97e-05	0.000386	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—psoriasis	1.85e-05	0.000363	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—psoriasis	1.71e-05	0.000336	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APOE—psoriasis	1.64e-05	0.000323	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—LEP—psoriasis	1.64e-05	0.000323	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NFKBIA—psoriasis	1.53e-05	0.000301	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TYK2—psoriasis	1.25e-05	0.000246	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—psoriasis	1.09e-05	0.000215	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL6—psoriasis	1.04e-05	0.000204	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JUN—psoriasis	1.02e-05	0.0002	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NFKB1—psoriasis	9.77e-06	0.000192	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CARM1—psoriasis	9.63e-06	0.000189	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—psoriasis	8.87e-06	0.000174	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—psoriasis	8.78e-06	0.000173	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—psoriasis	6.7e-06	0.000132	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL6—psoriasis	6.13e-06	0.000121	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAT—psoriasis	5.92e-06	0.000116	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—APOE—psoriasis	4.6e-06	9.04e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—psoriasis	4.01e-06	7.88e-05	CbGpPWpGaD
